Table 2 Vaccine effectiveness against documented SARS-CoV-2 infection, severe or critical illness, and death in matched case-control analysis by matching, age, gender, birthplace, date of illness onset, and residential district
Group | Documented SARS-CoV-2 infection, n = 612,597 | Control 1, n = 612,597 | VE (95% CI) (%) | Severe/critical illness, n = 1485 | Control 2, n = 5940 | VE (95% CI) (%) | Death, n = 568 | Control 3, n = 2272 | VE (95% CI) (%) |
|---|---|---|---|---|---|---|---|---|---|
Overall analysis | |||||||||
Unvaccinated | 104,901 (17.1) | 94,139 (15.4) | Reference | 1312 (88.4) | 3804 (64.0) | Reference | 535 (94.2) | 1639 (72.1) | Reference |
With any vaccine | 507,696 (82.9) | 518,458 (84.6) | 16.0 (15.1, 17.0) | 173 (11.6) | 2136 (36.0) | 88.6 (85.8, 90.8) | 33 (5.8) | 633 (27.9) | 91.6 (86.8, 94.6) |
Subgroup analysis | |||||||||
By gender | |||||||||
Malea | 289,105 (85.2) | 295,602 (87.1) | 18.9 (17.7, 20.2) | 126 (15.2) | 1505 (45.3) | 88.0 (84.5, 90.7) | 25 (8.3) | 438 (36.4) | 90.4 (84.1, 94.2) |
Femalea | 218,591 (80.0) | 222,856 (81.6) | 13.0 (11.6, 14.3) | 47 (7.2) | 631 (24.1) | 90.0 (84.6, 93.4) | 8 (3.0) | 195 (18.3) | 94.6 (84.9, 98.0) |
By age | |||||||||
3–17 yearsa | 25,875 (72.8) | 26,861 (75.6) | 20.1 (16.7, 23.4) | 0 (0.0) | 4 (100.0) | 90.6b (54.0, 98.1) | – | – | – |
18–39 yearsa | 198,590 (91.6) | 198,175 (91.4) | − 2.6 (− 4.8, − 0.4) | 6 (46.1) | 44 (84.6) | 1 (50.0) | 8 (100.0) | 93.4c (76.8, 98.1) | |
40–59 yearsa | 209,271 (91.6) | 210,530 (92.2) | 7.5 (5.5, 9.5) | 47 (49.5) | 344 (90.5) | 94.8 (88.4, 97.7) | 8 (36.4) | 78 (88.6) | |
60–79 yearsa | 71,698 (63.7) | 79,695 (70.8) | 29.8 (28.5, 31.1) | 90 (17.8) | 1288 (63.6) | 89.6 (86.3, 92.0) | 18 (12.2) | 322 (54.8) | 90.0 (82.3, 94.3) |
80+ yearsa | 2262 (11.8) | 3206 (16.6) | 36.7 (32.6, 40.5) | 30 (3.4) | 456 (13.1) | 79.8 (69.8, 86.4) | 6 (1.51) | 225 (14.2) | 93.5 (83.8, 97.4) |
By residential district | |||||||||
Urbana | 174,836 (77.5) | 181,748 (80.5) | 22.1 (20.8, 23.4) | 83 (10.2) | 1121 (34.3) | 88.1 (84.1, 91.1) | 12 (3.8) | 318 (25.3) | 93.6 (86.8, 96.9) |
Rurala | 332,860 (86) | 336,710 (87.0) | 10.7 (9.4, 12.1) | 90 (13.5) | 1015 (37.9) | 89.1 (84.9, 92.1) | 21 (8.3) | 315 (31.0) | 89.6 (81.5, 94.2) |
By vaccination course | |||||||||
Unvaccinated | 104,901 (17.1) | 94,139 (15.4) | Reference | 1312 (88.4) | 3804 (64.0) | Reference | 535 (94.2) | 1639 (72.1) | Reference |
Partial vaccination | 14,809 (2.4) | 13,376 (2.2) | 4.4 (1.9, 6.8) | 10 (0.7) | 67 (1.1) | 74.7 (49.1, 87.5) | 2 (0.4) | 26 (1.1) | 80.4 (16.4, 95.4) |
Full vaccination | 219,178 (35.8) | 220,764 (36.0) | 14.7 (13.7, 15.7) | 96 (6.5) | 866 (14.6) | 83.8 (79.0, 87.5) | 23 (4.0) | 257 (11.3) | 85.7 (75.6, 91.6) |
Booster vaccination | 273,709 (44.7) | 284,318 (46.4) | 18.0 (17.0, 18.9) | 67 (4.5) | 1203 (20.3) | 92.8 (90.2, 94.7) | 8 (1.4) | 350 (15.4) | 96.2 (92.0, 98.2) |
By vaccine type | 10 (0.7) | 67 (1.1) | 74.7 (49.1, 87.5) | 2 (0.4) | 26 (1.1) | 80.4 (16.4, 95.4) | |||
Unvaccinated | 104,901 (17.1) | 94,139 (15.4) | Reference | 1312 (88.4) | 3804 (64.0) | Reference | 535 (94.2) | 1639 (72.1) | Reference |
Inactivated vaccine | 485,190 (79.2) | 498,662 (81.4) | 16.3 (15.4, 17.2) | 170 (11.4) | 2114 (35.6) | 88.6 (85.8, 90.9) | 32 (5.6) | 622 (27.4) | 91.7 (86.9, 94.7) |
Adenovirus vector vaccine | 14,022 (2.3) | 13,817 (2.3) | 13.2 (10.9, 15.5) | 3 (0.2) | 16 (0.3) | 77.9 (15.6, 94.2) | 1 (0.2) | 4 (0.2) | NAd |
Recombined protein vaccine | 8484 (1.4) | 5979 (1.0) | NAd | 0 (0.0) | 6 (0.1) | NAd | 0 (0.0) | 7 (0.3) | NAd |